專利: US11236144B2/CN105431449B
簡介
PD-1異構體是免疫檢查點PD-1分子的獨特異構體。與野生型PD-1分子的免疫調節功能不同，PD-1異構體能夠促進炎症反應。
PD-1 異構體抑制平台能有效減低炎症反應
抗Δ42PD1阻斷抗體平台
我們的抗PD-1異構體抗體專利平台能有效阻止PD-1異構體與其關聯受體的相互作用，從而達到減低炎症反應的效果，繼而降低炎症引發的病理異常。
PD-1異構體抑制平台在腫瘤抑制中的作用
PD-1異構體誘導的炎症反應可導致T細胞衰竭和功能喪失，令到腫瘤細胞不能被清除。我們正在評估此抗體平台對逆轉T細胞衰竭來治療癌症的潛在治療效果。
參考文獻：
Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung AKL, et al. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. mAbs. 2015 Feb 18;7(3):620–9. Available from: https://doi.org/10.1080/19420862.2015.1016695
Cheung AKL, Kwok HY, Huang Y, Chen M, Mo Y, Wu X, et al. Gut-homing Δ42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection. Nature Microbiology. 2017 Aug 14;2(10):1389–402. Available from: https://doi.org/10.1038/s41564-017-0006-5
Liu L, Fang J, Gong R, Peng J, Cao T, Peng Q, et al. Isoformic PD-1 impedes B cell activation and function in HIV-1 infection. Cell Reports. 2025 Oct 1;44(10):116341. Available from: https://doi.org/10.1016/j.celrep.2025.116341
Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, et al. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022 Nov 30;72(8):1568–80. Available from: https://doi.org/10.1136/gutjnl-2022-327133